|
US8476239B2
(en)
*
|
2005-12-20 |
2013-07-02 |
Bristol-Myers Squibb Company |
Stable protein formulations
|
|
US9309316B2
(en)
|
2005-12-20 |
2016-04-12 |
Bristol-Myers Squibb Company |
Stable subcutaneous protein formulations and uses thereof
|
|
DK1969007T3
(da)
|
2005-12-20 |
2013-11-25 |
Bristol Myers Squibb Co |
Sammensætninger og fremgangsmåder til fremstilling af en sammensætning
|
|
AR058568A1
(es)
|
2005-12-20 |
2008-02-13 |
Bristol Myers Squibb Co |
Metodos para producir una composicion con moleculas ctla4-ig a partir de un medio de cultivo
|
|
US7915222B2
(en)
|
2008-05-05 |
2011-03-29 |
Bristol-Myers Squibb Company |
Method of preventing the development of rheumatoid arthritis in subjects with undifferentiated arthritis
|
|
RU2011118341A
(ru)
|
2008-10-06 |
2012-11-20 |
3-Д Матрикс, Лтд. (Jp) |
Агент для окклюзии тканей
|
|
DK2445616T3
(en)
*
|
2009-06-23 |
2018-06-06 |
Ge Healthcare Bio Sciences Ab |
SIMULATION DEVICES
|
|
GB201009676D0
(en)
*
|
2010-06-10 |
2010-07-21 |
Glaxosmithkline Biolog Sa |
Novel process
|
|
JP5847418B2
(ja)
|
2011-03-30 |
2016-01-20 |
富士フイルム株式会社 |
細胞接着性タンパク質
|
|
WO2012142434A2
(en)
*
|
2011-04-15 |
2012-10-18 |
THE UNITED STATES OF AMERICA, as represented by the secretary, Depart.of Healtth and Human Services |
Aav mediated ctla-4 gene transfer to treat sjogren's syndrome
|
|
US9511103B2
(en)
|
2011-04-20 |
2016-12-06 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
AAV mediated exendin-4 gene transfer to salivary glands to protect subjects from diabetes or obesity
|
|
TWI527590B
(zh)
*
|
2011-06-17 |
2016-04-01 |
艾瑞斯貿易公司 |
Ｆｇｆ－１８之凍乾調配物
|
|
AP2014007606A0
(en)
|
2011-10-07 |
2014-05-31 |
Takeda Pharmaceutical |
1-Arylcarbonyl-4-oxy-piperidine compounds useful for the treatment of neurodegenerative diseases
|
|
SMT202000091T1
(it)
|
2011-10-13 |
2020-05-08 |
Bristol Myers Squibb Co |
Polipeptidi anticorpali che antagonizzano cd40l
|
|
BR112014009146A8
(pt)
*
|
2011-10-18 |
2017-06-20 |
Coherus Biosciences Inc |
formulações de etanercepte estabilizadas com aminoácidos
|
|
US10485869B2
(en)
|
2011-10-18 |
2019-11-26 |
Coherus Biosciences, Inc. |
Etanercept formulations stabilized with meglumine
|
|
US9926365B2
(en)
|
2012-06-29 |
2018-03-27 |
Bristol-Myers Squibb Company |
Methods for reducing glycoprotein aggregation
|
|
WO2014008400A2
(en)
*
|
2012-07-06 |
2014-01-09 |
3-D Matrix, Inc. |
Fill-finish process for peptide solutions
|
|
HK1209343A1
(en)
|
2012-07-09 |
2016-04-01 |
Coherus Biosciences, Inc. |
Etanercept formulations exhibiting marked reduction in sub-visible particles
|
|
EP2877589B1
(en)
|
2012-07-26 |
2024-03-06 |
Momenta Pharmaceuticals, Inc. |
Glycoproteins with anti-inflammatory properties
|
|
WO2014036468A2
(en)
|
2012-08-31 |
2014-03-06 |
The United States Of America, As Represented By The Secretary, Department Of Health & Human Services |
Aav mediated aquaporin gene transer to treat sjogren's syndrome
|
|
PE20150964A1
(es)
|
2012-09-07 |
2015-07-25 |
Coherus Biosciences Inc |
Formulaciones acuosas estables de adalimumab
|
|
SI2895188T1
(en)
|
2012-09-11 |
2018-05-31 |
Coherus Biosciences, Inc. |
CORRECTED QUALITY ETHANERCEPT WITH HIGH QUALITY AND EXCELLENT EXPERIENCE
|
|
US10450361B2
(en)
|
2013-03-15 |
2019-10-22 |
Momenta Pharmaceuticals, Inc. |
Methods related to CTLA4-Fc fusion proteins
|
|
WO2014186310A1
(en)
|
2013-05-13 |
2014-11-20 |
Momenta Pharmaceuticals, Inc. |
Methods for the treatment of neurodegeneration
|
|
CN103385852B
(zh)
*
|
2013-08-06 |
2015-03-11 |
南京正大天晴制药有限公司 |
一种盐酸法舒地尔注射液及其制备方法
|
|
IL312865B2
(en)
|
2013-09-11 |
2025-06-01 |
Eagle Biologics Inc |
Liquid protein formulations containing viscosity-lowering agents
|
|
WO2015057622A1
(en)
|
2013-10-16 |
2015-04-23 |
Momenta Pharmaceuticals, Inc. |
Sialylated glycoproteins
|
|
BR112016019510A2
(pt)
|
2014-03-10 |
2017-10-24 |
3 D Matrix Ltd |
esterilização e filtração de composições de peptídeos
|
|
RU2016139369A
(ru)
|
2014-03-10 |
2018-04-10 |
3-Д Матрикс, Лтд. |
Композиции самоорганизующихся пептидов
|
|
CN106132429A
(zh)
|
2014-03-19 |
2016-11-16 |
百时美施贵宝公司 |
使用针对cd40l的域抗体治疗移植物排斥的方法
|
|
US11058768B2
(en)
*
|
2014-04-16 |
2021-07-13 |
Biocon Ltd. |
Stable protein formulations comprising a molar excess of sorbitol
|
|
US20170042972A1
(en)
|
2014-04-25 |
2017-02-16 |
Chetan KARYEKAR |
Use of ctla4 compound for achieving drug-free remission in subjects with early ra
|
|
US11357857B2
(en)
|
2014-06-20 |
2022-06-14 |
Comera Life Sciences, Inc. |
Excipient compounds for protein processing
|
|
US10478498B2
(en)
|
2014-06-20 |
2019-11-19 |
Reform Biologics, Llc |
Excipient compounds for biopolymer formulations
|
|
WO2015196091A1
(en)
|
2014-06-20 |
2015-12-23 |
Reform Biologics, Llc |
Viscosity-reducing excipient compounds for protein formulations
|
|
SG11201609706VA
(en)
|
2014-06-23 |
2017-01-27 |
Novartis Ag |
Site specific protein modifications
|
|
US10588980B2
(en)
|
2014-06-23 |
2020-03-17 |
Novartis Ag |
Fatty acids and their use in conjugation to biomolecules
|
|
EP3157947A1
(en)
|
2014-06-23 |
2017-04-26 |
Novartis AG |
Hsa-gdf-15 fusion polypeptide and use thereof
|
|
AU2015325055B2
(en)
|
2014-10-01 |
2021-02-25 |
Eagle Biologics, Inc. |
Polysaccharide and nucleic acid formulations containing viscosity-lowering agents
|
|
JP6781508B2
(ja)
|
2014-11-18 |
2020-11-04 |
塩野義製薬株式会社 |
安定化されたペプチド組成物
|
|
MA41580A
(fr)
|
2015-01-23 |
2017-11-29 |
Novartis Ag |
Conjugués d'acides gras de l'apeline synthétique présentant une demi-vie améliorée
|
|
MA41459A
(fr)
|
2015-02-03 |
2017-12-12 |
Als Therapy Development Inst |
Anticorps anti-cd40l et méthodes pour traiter des maladies ou des troubles liés aux cd40l
|
|
MA53355A
(fr)
|
2015-05-29 |
2022-03-16 |
Agenus Inc |
Anticorps anti-ctla-4 et leurs procédés d'utilisation
|
|
DK3347031T3
(da)
*
|
2015-09-11 |
2021-04-26 |
Nutrition & Biosciences Usa 1 Llc |
Sammensætning, der omfatter et protein og en polyalkoxyfedtforbindelse
|
|
US11229702B1
(en)
|
2015-10-28 |
2022-01-25 |
Coherus Biosciences, Inc. |
High concentration formulations of adalimumab
|
|
LT3386541T
(lt)
|
2015-12-07 |
2020-10-26 |
Merck Patent Gmbh |
Vandeninė farmacinė kompozicija, apimanti anti-pd-1 antikūną avelumabą
|
|
JP6946304B2
(ja)
|
2015-12-22 |
2021-10-06 |
ノバルティス アーゲー |
増殖分化因子１５（ｇｄｆ−１５）を使用して代謝障害を処置するまたは軽快させる方法
|
|
US10814038B2
(en)
|
2016-01-06 |
2020-10-27 |
3-D Matrix, Ltd. |
Combination compositions
|
|
EP3192805A1
(en)
|
2016-01-15 |
2017-07-19 |
Humanitas Mirasole S.p.A. |
Inhibitors of t cell activation or stimulation and uses thereof
|
|
US11071782B2
(en)
|
2016-04-20 |
2021-07-27 |
Coherus Biosciences, Inc. |
Method of filling a container with no headspace
|
|
DK3551660T5
(da)
|
2016-12-07 |
2024-09-02 |
Agenus Inc |
Anti-ctla-4-antistoffer og fremgangsmåder til anvendelse deraf
|
|
KR102840867B1
(ko)
|
2017-05-24 |
2025-07-30 |
에이엘에스 테라피 디벨럽먼트 인스티튜트 |
치료용 항-cd40 리간드 항체
|
|
WO2019123427A1
(en)
|
2017-12-22 |
2019-06-27 |
Novartis Ag |
Methods of treating metabolic disorders with fgf21 variants
|
|
CN108014338A
(zh)
*
|
2018-01-22 |
2018-05-11 |
安徽未名生物医药有限公司 |
一种注射用巴利昔单抗冻干粉针及其制备方法
|
|
JP7449243B2
(ja)
*
|
2018-05-25 |
2024-03-13 |
ドクター レディズ ラボラトリーズ リミテッド |
安定な融合タンパク質製剤
|
|
JP2021525255A
(ja)
*
|
2018-05-25 |
2021-09-24 |
ドクター レディズ ラボラトリーズ リミテッド |
ＣＴＬＡ４−Ｉｇ融合タンパク質製剤
|
|
WO2020003139A2
(en)
*
|
2018-06-26 |
2020-01-02 |
Lupin Limited |
Stable lyophilized dosage form of protein
|
|
CN113528510A
(zh)
*
|
2018-06-29 |
2021-10-22 |
武汉纽福斯生物科技有限公司 |
治疗遗传性视神经病变的组合物和方法
|
|
EP3887393A1
(en)
|
2018-11-26 |
2021-10-06 |
Novartis AG |
Lpl-gpihbp1 fusion polypeptides
|
|
WO2020148338A1
(en)
|
2019-01-15 |
2020-07-23 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Mutated interleukin-34 (il-34) polypeptides and uses thereof in therapy
|
|
US20220098252A1
(en)
|
2019-01-25 |
2022-03-31 |
Ospedale San Raffaele S.R.L. |
Inhibitor of dux4 and uses thereof
|
|
GB201913697D0
(en)
|
2019-09-23 |
2019-11-06 |
King S College London |
DAP10/DAP12 fusion polypeptides
|
|
US20230071973A1
(en)
*
|
2019-12-20 |
2023-03-09 |
Anthos Therapeutics, Inc. |
Pharmaceutical formulations and dosage regimens for factor xi/xia antibodies
|
|
GB202003277D0
(en)
|
2020-03-06 |
2020-04-22 |
King S College London |
Therapeutic agents
|
|
GB202007655D0
(en)
|
2020-05-22 |
2020-07-08 |
King S College London |
Chimeric nkg2d protein
|
|
WO2022162704A1
(en)
*
|
2021-02-01 |
2022-08-04 |
Dr. Reddy's Laboratories Limited |
Compositions comprising fusion protein and analytical attributes thereof
|
|
KR20230159476A
(ko)
|
2021-03-23 |
2023-11-21 |
킹즈 컬리지 런던 |
NKG2D, CXCR2 및 dap10/dap12 융합 폴리펩티드를 포함하는 조성물 및 이의 사용 방법
|
|
CN113925963B
(zh)
*
|
2021-10-15 |
2023-08-11 |
江苏太平洋美诺克生物药业股份有限公司 |
一种稳定的包含抗cd147单克隆抗体的药物制剂
|
|
GB202214120D0
(en)
|
2022-09-27 |
2022-11-09 |
King S College London |
Compositions comprising NKG2D, CXCR2, and DAP10/DAP12 fusion polypeptides and methods of use thereof
|
|
WO2024069420A2
(en)
*
|
2022-09-29 |
2024-04-04 |
Pfizer Inc. |
Immunogenic compositions comprising an rsv f protein trimer
|
|
EP4389762A1
(en)
|
2022-12-23 |
2024-06-26 |
Ospedale San Raffaele S.r.l. |
Inhibitors of dux4 activity and their use in therapy.
|
|
WO2025196207A1
(en)
|
2024-03-20 |
2025-09-25 |
King's College London |
Compositions and methods for use in depleting senescent cells and treating aging
|
|
WO2026021575A1
(zh)
*
|
2024-07-26 |
2026-01-29 |
鸿运华宁（杭州）生物医药有限公司 |
一种gipr抗体融合蛋白质的药用稳定溶液制剂及其应用
|